Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05076175Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Primary completion
- Jul 2032
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of ozanimod in ulcerative colitis (UC), sponsored by Bristol Myers Squibb. Started May 2022; status: recruiting.
02
Drugs
ozanimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05076175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076175.